1.A study co-conducted by Director Liu Shuangyou and Director Yu Xinjian was selected as an oral report at the annual meeting,"CD58 Could Be as a Leukemic Marker in Relapsed/Refractory B-ALL Patients after Multiline Therapies".

2.Head Nurse Zhang Na made a poster display with the theme of"Effects of BMI,Albumin and NRS 2002 Changes on Prognosis in Patients with Hematological Malignancies during CAR-T Treatment".

3.Dr.Tan Yue made a poster display with the theme of"Efficacy and Safety of Donor-Derived CD7 CAR-T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma:Interim Analysis from a Phase 2 Trial".

4.Dr.Zheng Peihao made a poster display with the theme of"Exploring the Efficiency and Survival of CAR-T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities".

5.Prof.Li Zhihui made a poster display with the theme of"Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation".

6.Dr.Shi Hui made a poster display with the theme of"Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients:Single-Arm,Open-Label,Phase I Study"and"Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy".

7.Prof.YangFan made a poster display with the theme of"Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy".